BioXcel Therapeutics, Inc. (BTAI): Price and Financial Metrics
BTAI Price/Volume Stats
| Current price | $0.57 | 52-week high | $4.25 |
| Prev. close | $0.58 | 52-week low | $0.50 |
| Day low | $0.54 | Volume | 174,065 |
| Day high | $0.58 | Avg. volume | 823,493 |
| 50-day MA | $0.60 | Dividend yield | N/A |
| 200-day MA | $1.60 | Market Cap | 24.44M |
BTAI Stock Price Chart Interactive Chart >
BioXcel Therapeutics, Inc. (BTAI) Company Bio
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. The company was founded in 2017 and is based in Branford, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.
BTAI Price Returns
| 1-mo | 0.74% |
| 3-mo | -16.24% |
| 6-mo | -69.19% |
| 1-year | -85.12% |
| 3-year | -97.76% |
| 5-year | -90.53% |
| YTD | -80.68% |
| 2023 | -86.27% |
| 2022 | 5.66% |
| 2021 | -56.00% |
| 2020 | 216.22% |
| 2019 | 278.50% |
Loading social stream, please wait...